Pfizer: Merger picture - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer: Merger picture

Jun 27, 2002

Pfizer Inc. emerged as the world's largest pharma company in early 2000, when it snatched Warner Lambert from the clutches of rival suitor American Home Products (AHP). A US$ 90 bn acquisition of Warner Lambert was the largest ever in the history of global pharma industry. The merged entity now has sales close to US$ 30 bn with highest R&D budget in the pharma industry. With Warner came cholesterol-fighter Lipitor, the drug market's No. 1 seller with $6 bn in annual revenues, apart from other major brands. Following the global merger, Pfizer India also decided to merge Warner Lambert subsidiary, Parke Davis with itself. The company is expected to announce the merger ratio today. We expect the ratio to be 1:3 (i.e. 3 shares of Parke Davis for every share of Pfizer).

Pfizer-Parke Davis - A robust entity
The merged entity in India would have robust financial numbers with sales expected around Rs 6 bn, leading to a position in the list of top five domestic pharma players and a combined market share of 3.2% in the domestic industry.

Rs m Pfizer* Parke Davis** Merged Entity***
Net Sales 3,206 2,134 5,755
Operating Margins (%) 7.2% 14.0% 11.8%
Net Profit 475 250 812
EPS (Rs.) 20.3 20.8 29.5
*- Latest available 12 month results **- Annualised 12 months results
***- Expected numbers for 12 months ending Nov'02
Apart from financial consolidation, the merger with Parke Davis is expected to add significant brands to the company's already impressive product portfolio. Pfizer would inherit brands such as Benadryl, Gelusil and Listerine from Parke Davis.

Particulars Pfizer Parke Davis Merged
ORG Rank 11 23 5
No. of Products 24 54 78
Sales per brand (Rs m) 134 40 74
As shown in the above table, while Pfizer brings on the table a small portfolio of mega brands, Parke Davis, brings a larger portfolio of products. While on one hand, the merger would help Pfizer create a strong hold in the OTC segment; the companyís aggressive marketing field force would have a large product portfolio to push. Pfizerís marketing team is considered to be the best in the industry. Barring Benadryl, there is little overlap in the product profiles of both the companies even in common therapeutic segments. Even after the merger, the sales value per brand for Pfizer is expected to be impressive, which clearly vouches for its strong brand portfolio.

Both Pfizer and Parke Davis have introduced few new products due to weak patent laws and competition in the formulations market in the domestic market. Considering the parentís stand on new product introductions, the situation is not expected to improve. The company now seems to be tackling this by tying-up with local pharmaceutical companies. The tie -up with Shanta Biotech, to market the latterís hepatitis-B vaccine was a unique combination of innovative product and strong marketing. The company is also awaiting other products from the Shanta Biotech stable.

Pfizer- Few but strong brands
Company Ranking in
terms of sales*
No. of
Products
Sales/Product
(Rs m)
Aventis 6 55 94
Pfizer 5 78 74
GlaxoSmithKline 1 210 53
Ranbaxy 2 237 35
Nicholas Piramal 4 217 25
Cipla 3 358 21
*- Expected rankings post Pfizer- Parke Davis merger

Equitymaster requests your view! Post a comment on "Pfizer: Merger picture". Click here!

  

More Views on News

PFIZER 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of PFIZER for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 30, 2021 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS